ClinicalTrials.gg
CompletedNCT05364255Updated Jun 21, 2024

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

A Phase 1 interventional study of [14C]AZD9833 Oral Solution, 75 mg in ER-positive, HER2-negative Breast Cancer, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
50 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Breast Neoplasms by AstraZeneca — 20 open to participants now, 50 under way, 24 of them phase 3. Breast Neoplasms · AstraZeneca.

Enrollment
122nd of 125
6 · median 148
Started
2022
with 9 others
Phase 1
30 of 198
1 open now
Registered
154th of 198
by date

Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 122nd largest by enrollment of the 125 interventional ones that give a count, is one of 10 that started in 2022, is one of 30 in phase 1, and was the 154th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

20 of the 198 studies in Breast Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 50 Years to 70 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Breast Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

The Sponsor is developing the test medicine, AZD9833 for the potential treatment of estrogen receptor (ER)-positive breast cancer.

This single-part, healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

This study will take place at one non-NHS site, and will consist of a single study period involving up to 6 post-menopausal female volunteers, aged between 50 to 70 years.

Read the detailed description

The Sponsor is developing the test medicine, AZD9833 for the potential treatment of estrogen receptor (ER)-positive breast cancer.

Breast cancer is the second most common type of cancer in the UK and worldwide. Most women diagnosed with breast cancer are over the age of 50, but younger women and men can also get breast cancer. AZD9833 has the potential to prevent ER activity and increase overall survival in advanced breast cancer patients.

This single-part, healthy volunteer study will try to identify how the test medicine is taken up, broken down and removed from the body. To help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body. The safety and tolerability of the test medicine will also be studied.

This study will take place at one non-NHS site, and will consist of a single study period involving up to 6 post-menopausal female volunteers, aged between 50 to 70 years.

On Day 1, volunteers will receive a 75 mg dose of [14C]AZD9833 oral solution in the fasted state (on an empty stomach).

Volunteer's blood, urine and faeces will be taken throughout the study for analysis of the test medicine and it's breakdown products (metabolites) and for volunteer safety.

Volunteers will remain in the clinical unit until Day 8, however if the relevant radioactivity criteria have not been met, volunteers may be required to remain at the clinic until Day 10. If relevant criteria have not been met at this point, home collections of urine and/or faeces may be required.

Volunteers are expected to be involved in this study for approximately 6 weeks from screening to discharge.

03

Conditions studied

  • ER-positive, HER2-negative Breast Cancer

Browse trials for

Keywords

  • Breast cancer
04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written prior to any study specific procedures
  • Aged between 50 to 70 years inclusive at the time of signing informed consent
  • Healthy females, defined as post-menopausal by fulfilling the following criterion:

    (a) amenorrhoea for at least 12 months following cessation of all exogenous hormonal treatments and without an alternative medical or surgical cause and confirmed by an FSH result of ≥30 IU/L

  • Must be willing and able to communicate and participate in the whole study
  • Have a (BMI) between 19.0 to 35.0 kg/m2, weigh at least 50 kg and no more than 100 kg inclusive as measured at screening.
  • Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day)

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
  • History or presence of GI, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
  • Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP
  • History of or ongoing clinically significant visual disturbances including but not limited to visual hallucinations, migraine with visual symptoms, blurred vision, frequent floaters/flashes associated with other symptoms such as dizziness
  • Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, at screening as judged by the Investigator
  • Any clinically significant abnormal findings in vital signs at screening as judged by the Investigator, including systolic BP \<100 mmHg, diastolic BP \<50 mmHg or heart rate \<50 bpm. Vital signs outside these limits can be repeated once for confirmation
  • Any clinically significant abnormalities on 12-lead at screening, as judged by the Investigator, including non-sinus rhythms, PR interval \<120 msec or >220 msec, ventricular rate \<50 bpm or >100 bpm, QRS interval >120 msec, or >470 msec as a mean of triplicate. ECGs can be repeated once in triplicate if parameters are outside these limits for confirmation
  • Evidence of renal impairment at screening, as indicated by an estimated (CLcr) of \<60 mL/min/1.73m2 using the Cockcroft-Gault equation
  • Any positive result on screening for serum surface antigen (HBsAg), antibody (HCV Ab), and (HIV) 1 and 2 antibodies
  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 4 weeks prior to Day 1, or less than 5 elimination half-lives + 6 days prior to Day 1, whichever is longer. Note: subjects consented and screened, but not administered IMP in this study or a previous Phase I study, are not excluded
  • Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening
  • History of severe allergy/ or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9833. Hay fever is allowed unless it is active
  • Any known or suspected hypersensitivity or to the components of the study drug, AZD9833, judged to be clinically relevant by the investigator
  • Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months prior to screening
  • A confirmed breath carbon monoxide reading of greater than 10 ppm at screening or admission
  • Positive screen for drugs of abuse at screening or on each admission to the study centre
  • Regular alcohol consumption >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
  • A confirmed positive alcohol breath test at screening or admission
  • Subjects who are taking, or have taken:

    1. any prescribed or over-the-counter drug (other than up to 4 g of paracetamol per day ) or herbal remedies in the 14 days before IMP administration or longer if the medication has a long half-life. COVID-19 vaccines are accepted concomitant medications. Exceptions may apply, as determined by the Investigator, if each of the following criteria are met: medication with a short half-life if the is such that no PD activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study
    2. atropine or atropine containing drugs, in the 14 days before IMP administration
    3. Systemic oestrogen-containing hormone replacement therapy in the 6 months prior to IMP administration
  • Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks or 5 half-lives (whichever is longer) or any drugs with a known risk, potential risk or conditional risk for QTca prolongation as defined and outlined in the Credible Meds website within 4 weeks prior to Day 1
  • Subjects who do not agree to avoid the to use warfarin or phenytoin (and other coumarin-derived vitamin K antagonist anticoagulants) for 2 weeks after administration of IMP
  • Excessive intake of caffeine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the Investigator. Excessive intake of caffeine defined as the regular consumption of more than 600 mg of caffeine per day (e.g., >5 cups of coffee) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the clinical unit
  • Involvement of any Astra Zeneca, Quotient or study site employee or their close relatives
  • Subjects who report to have previously received AZD9833 in the last 12 months
  • Judgment by the Investigator that the volunteer should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements
  • Evidence of current SARS-CoV-2 infection
  • Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study
  • Vulnerable subjects, e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator or delegate at screening
  • Subjects with an anticipated need for major surgery and/or any surgery requiring general anaesthesia during the participation in the study (which may entail administration of atropine in an anaesthetic context)
  • Failure to satisfy the Investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]AZD9833 (D8532C00005)

    Oral Solution, 75 mg (NMT 0.67 MBq)

    Drug: [14C]AZD9833 Oral Solution, 75 mg

Interventions

  • Drug[14C]AZD9833 Oral Solution, 75 mg

    Oral Solution, 75 mg (NMT 0.67 MBq) - oral, fasted

06

What researchers measure

Primary outcomes

  1. The cumulative amount of AZD9833 excreted (CumAe)

    Assessment of the total radioactivity by measuring the cumulative amount of AZD9833 excreted

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  2. The cumulative amount of AZD9833 excreted, expressed as a percentage of the radioactive dose administered (Cum%Ae)

    Assessment of the total radioactivity, expressed as a percentage, by measuring the cumulative amount of AZD9833 excreted

    Time frame: Urine and faecal samples collected from pre-dose until 168 hours post-dose

  3. Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites in plasma by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Plasma samples collected from pre-dose until 168 hours post-dose

  4. Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites in urine by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Urine samples collected from pre-dose until 168 hours post-dose

  5. Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Assessment of metabolites in faeces by liquid chromatography-radiochemical-detection and subsequent mass spectrometry

    Time frame: Faeces samples collected from pre-dose until 168 hours post-dose

Secondary outcomes

  1. The amount of total radioactivity eliminated in urine (Ae)

    Assessment of the total radioactivity, by measuring the amount of AZD9833 excreted in urine by interval

    Time frame: Urine samples collected from pre-dose until 168 hours post-dose

  2. The amount of total radioactivity eliminated in urine expressed as a percentage of the radioactive dose administered (%Ae)

    Assessment of the total radioactivity, expressed as a percentage, by measuring the amount of AZD9833 excreted in urine by interval

    Time frame: Urine samples collected from pre-dose until 168 hours post-dose

  3. The cumulative amount of AZD9833 excreted in urine (CumAe)

    Assessment of the total radioactivity by measuring the cumulative amount of AZD9833 excreted in faeces.

    Time frame: Urine samples collected from pre-dose until 168 hours post-dose

  4. The cumulative amount of AZD9833 excreted in urine, expressed as a percentage of the radioactive dose administered (Cum%Ae)

    Assessment of the total radioactivity, expressed as a percentage, by measuring the cumulative amount of AZD9833 excreted in urine

    Time frame: Urine samples collected from pre-dose until 168 hours post-dose

  5. The amount of total radioactivity eliminated in faeces (Ae)

    Assessment of the total radioactivity, by measuring the amount of AZD9833 excreted in faeces by interval

    Time frame: Faeces samples collected from pre-dose until 168 hours post-dose

  6. The amount of total radioactivity eliminated in faeces expressed as a percentage of the radioactive dose administered (%Ae)

    Assessment of the total radioactivity, expressed as a percentage, by measuring the amount of AZD9833 excreted in faeces by interval

    Time frame: Faeces samples collected from pre-dose until 168 hours post-dose

  7. The cumulative amount of AZD9833 excreted in faeces (CumAe)

    Assessment of the total radioactivity by measuring the cumulative amount of AZD9833 excreted in faeces.

    Time frame: Faeces samples collected from pre-dose until 168 hours post-dose

  8. The cumulative amount of AZD9833 excreted in faeces, expressed as a percentage of the radioactive dose administered (Cum%Ae)

    Assessment of the total radioactivity, expressed as a percentage, by measuring the cumulative amount of AZD9833 excreted in faeces

    Time frame: Faeces samples collected from pre-dose until 168 hours post-dose

  9. Time to maximum concentration (tmax) for AZD9833 and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the time to maximum concentration (tmax)

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  10. Maximum observed concentration (cmax) for AZD9833 and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the maximum observed concentration (cmax)

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  11. Area under the curve from time 0 to the time of last measurable concentration for AZD9833 and total radioactivity (AUC0-t)

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the area under the curve from time 0 to the time of last measurable concentration

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  12. Area under the curve from time 0 extrapolated to infinity for AZD9833 and total radioactivity (AUC0-inf)

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the area under the curve from time 0 extrapolated to infinity

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  13. Area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity (AUC%extr) and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the area under the curve from time of the last measurable concentration to infinity as a percentage of the area under the curve extrapolated to infinity

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  14. Terminal elimination half-life for AZD9833 (t1/2) and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the terminal elimination half-life

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  15. First order rate constant associated with the terminal (log-linear) portion of the curve for AZD9833 (λz) and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the First order rate constant associated with the terminal (log-linear) portion of the curve

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  16. Total body clearance calculated after a single extravascular administration for AZD9833 (CL/F) and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the total body clearance calculated after a single extravascular administration

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  17. Apparent volume of distribution based on the terminal phase for AZD9833 (Vz/F) and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the apparent volume of distribution based on the terminal phase

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  18. Renal clearance for AZD9833 (CLr) and total radioactivity

    Assessment of pharmacokinetics of AZD9833 and total radioactivity by measuring the renal clearance

    Time frame: Collection of plasma samples from pre-dose to 168 hours post-dose

  19. Evaluation of whole blood:plasma concentration ratios for total radioactivity

    Assessment of total radioactivity in whole blood and plasma

    Time frame: Collection of blood samples until 168 hours post dose

  20. Number of AE's experienced by subjects

    Safety and tolerability assessed through the incidence of AEs

    Time frame: AEs recorded from the time of informed consent until the follow up visit (approx 6 weeks)

07

Study locations

1 site
  • Research Site
    Ruddington, NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2022, 1 month.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 1 month is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2022
First posted
May 6, 2022
StartActual
May 10, 2022
Primary completionActual
Jun 20, 2022
CompletionActual
Jun 20, 2022
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05364255
Lead sponsor
AstraZeneca
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
May 6, 2022
Start date
May 10, 2022
Primary completion
Jun 20, 2022
Completion
Jun 20, 2022
Last update
Jun 21, 2024

Study contacts

Somasekhara Menakuru, MBBS, MS, MRCS, DPM, MFPM
principal investigator · Quotient Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion